Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930005 · ClinicalTrials.gov registry record · Phase 2
Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02930005 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 8 participants.
The verdict
NCT02930005, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. Half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.
Interventions
- DRUG Meclofenamic acid
- DRUG Pentosan polysulfate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-08-07 |
| Est. Completion | 2016-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930005
The ClinicalTrials.gov registry entry for NCT02930005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Meclofenamic acid is the first listed.
NCT02930005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02930005 about?
NCT02930005 is a clinical study titled "Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders". This study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. Half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.
What is the current status of trial NCT02930005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2015-08-07. Estimated completion is 2016-10-06.
What interventions are being tested in trial NCT02930005?
The interventions under investigation include: Meclofenamic acid (DRUG), Pentosan polysulfate sodium (DRUG).
Who is sponsoring clinical trial NCT02930005?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.